Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab, formerly known as Numax(R), is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its first pivotal trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated a 26-percent reduction in RSV hospitalizations due to RSV and a 50-percent reduction in the incidence of RSV lower respiratory tract infections requiring outpatient management, its secondary endpoint.

About Synagis

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RS
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "North American Active Wound ... Application (Surgical Wound, & Ulcer), by End-User (In-Patient, ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... is estimated to grow at a CAGR of ...
(Date:5/21/2015)... May 21, 2015  CryoLife, Inc. (NYSE: CRY ... focused on cardiac and vascular surgery, announced today that ... dividend for the second quarter 2015 of $0.03 per ... of $0.03 per share will be paid on June ... of June 12, 2015.  The ex-dividend date for the ...
(Date:5/21/2015)... WASHINGTON , May 21, 2015 ... following statement regarding the Medicare Part D offsets ... Century Cures initiative: "If the 21st Century ... billions from America,s premier health program – Medicare ... it may yield down the road. ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... Explore the Effects of Eligen(R) Delivery Technology and ... in Postmenopausal Women, CEDAR KNOLLS, N.J., Aug. ... announced today that Novartis Pharma AG,has finished recruitment ... and efficacy of Salmon Calcitonin and Emisphere,s proprietary,Eligen(R) ...
... Patients with Cystoid Macular ... ... Bioscience, Inc., (IBI),a privately held ophthalmic pharmaceutical company, announced today that,enrollment ... the,safety and efficacy of its lead product, IBI-20089, in patients with,cystoid ...
Cached Medicine Technology:Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment 2Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate 2
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... May 22, 2015 “It’s like ... SLP, RAC-CT, CHHRP-QT, Vice President of Clinical Operations/Education ... important ‘language’ that impacts how care is coded ... in long term care reimbursement, operations and compliance ... and talent management, launches a new series of ...
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
(Date:5/22/2015)... 22, 2015 Memorial Day weekend is typically ... is offering some tips to help promote safe travel. ... will be 383 traffic fatalities this Memorial Day weekend. Amica ... Highway Traffic Safety Association: , , ... is wearing a seatbelt, whether they’re driving or riding along ...
(Date:5/22/2015)... 2015 Power Systems is proud to announce ... race season. Drobeck is in his second year of racing ... with the Missoula Fire Department in Missoula, MT. He entered ... 2014. During his career, he has had 15 1st Place ... top 10 finishes in all seven of his 2014 races, ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... Reading a book can satisfy the crucial human need for ... 140 university students who were given 30 minutes to read ... Twilight or the wizard novel Harry Potter and ... of either vampires or wizards. The participants were then ...
... rising levels of cardiovascular disease (CVD) in the Asia Pacific ... the first time- the Society will send an official delegation ... The 18th edition of the APCC meeting will be ... 2011. The ESC deputation will present an educational programme called ...
... Chief of both the Division of Allergy and Inflammation and ... Center (BIDMC), is the recipient of an NIH MERIT ... A Professor of Medicine at Harvard Medical School, Weller received ... Functioning." An acronym for the Method to Extend Research ...
... is regarded as the most thorough way to ... procedure can also be painful. Scientists and engineers ... reduce patient discomfort while also ensuring the accuracy ... of Engineering led by Associate Professor of Mechanical ...
... accepted for publication in The Endocrine Society,s Journal of ... and white children with vitamin D deficiency both had higher ... levels of fat just under their skin and white children ... their internal organs. Studies in adults and children have ...
... The Scripps Research Institute and Tampa,s Moffitt Cancer ... study the formation and progression of prostate cancer. Of ... Scripps Research, with the remaining $138,380 supporting Moffitt Cancer ... Institutes of Health (NIH) will fund research to advance ...
Cached Medicine News:Health News:The European Society of Cardiology organizes educational program in Asia 2Health News:BIDMC's Peter Weller, M.D., receives NIH MERIT Award 2Health News:A less painful colonoscopy 2Health News:A less painful colonoscopy 3Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Scripps Research wins more than $2 million to study prostate cancer 2
... nRBC-Chex for LH is a nucleated red blood ... precision of the Coulter LH 750/LH 755 hematology ... The assay provides for the Coulter LH 750/LH ... packaged in plastic, cap-pierceable vials. nRBC-Chex for LH ...
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions....
... 12 Extend is a three-part differential control assayed ... STKR, J Series, T Series, AcT/AcT diff/AcT diff2, ... 1500, 1600, 1700, and 1800; ABX Micros 60; ... Extend has an open-vial stability of 30 days ...
... 5-part differential control that controls all parameters, ... LH 750/LH 755, MAXM and HmX instruments. ... values for all three levels. White blood ... are within clinically significant ranges. This unique ...
Medicine Products: